Yıl: 2022 Cilt: 26 Sayı: 1 Sayfa Aralığı: 1 - 12 Metin Dili: İngilizce İndeks Tarihi: 26-06-2022

A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study

Öz:
Objective: The primary objective of the CAPTURE study was to estimate the prevalence of cardiovascular disease (CVD) in adults with Type 2 diabetes mellitus (T2DM) across 13 countries from 5 continents. Here, we present the findings from Türkiye. Material and Methods: The non-interventional, cross-sectional CAPTURE study (NCT03811288; NCT03786406) was conducted across 15 centers in Türkiye. Standardized demographic and clinical data were collected from adults with T2DM who were treated by primary or specialist care physicians. The prevalences of CVD and its 7 subtypes were estimated. Descriptive statistics were used for data analysis. Results: Amongst the 801 participants (n=200 from primary care, n=601 from specialist care) with T2DM enrolled, 250 had established CVD, an estimated weighted prevalence of 31.2% (28.0-34.4) 95% confidence interval. Atherosclerotic CVD contributed to the majority (85.6%) of the CVD cases. An estimated 24.0% of the Türkiye sample had coronary heart disease (CHD). Heart failure was the second most predominant CVD subtype in Türkiye is correct sample (5.4%), followed by cardiac arrhythmia and conduction abnormalities (4.7%). Sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists with cardiovascular (CV) benefits were prescribed to 17.5% and 0.1% of the patients, respectively. Conclusion: Approximately 30% of participants with T2DM had established CVD in the CAPTURE Türkiye population, comparable to the global pooled prevalence. CHD was the major contributor and encompassed approximately 75% of the CVD cases. The use of glucose-lowering medication with CV benefits was low compared to the global pooled population, which may be due to the lack of reimbursement of these medications in Türkiye.
Anahtar Kelime:

Türkiye’de Erişkin Tip 2 Diabetes Mellituslularda Güncel Kardiyovasküler Hastalık Prevalansının Kesitsel Bir Çalışması: CAPTURE Türkiye Çalışması

Öz:
Amaç: CAPTURE çalışmasında, 5 kıtadan 13 ülkede erişkin Tip 2 diabetes mellituslu (T2DM) bireylerde kardiyovasküler hastalık (KVH) prevalansını ortaya çıkarmak amaçlanmıştır. Burada, Türk kohortundan elde edilen bilgiler sunulmaktadır. Gereç ve Yöntemler: Girişimsel olmayan kesitsel bir çalışma olan CAPTURE (NCT03811288; NCT03786406), Türkiye’de 15 merkezde tamamlandı. Birinci basamak hekimleri* ve uzman hekimler** tarafından tedavi edilen erişkin T2DM’lilere ait standardize demografik ve klinik veriler toplandı. Elde edilen verilerden KVH ve 7 alt tipinin prevalans tahminleri hesaplandı. Veriler tanımlayıcı istatistiksel yöntemlerle analiz edildi. Bulgular: Çalışmaya, T2DM’li 801 (birinci basamak* n=200, uzman** n=601) hasta kaydedildi. Çalışmaya katılan hastaların 250’sine KVH tanısı konmuştur ve KVH’nin tahmini ağırlıklı prevalansı %31,2’dir (%95 güven aralığı, 28,0-34,4). KVH vakalarının çoğunluğu aterosklerotik KVH (%85,6) idi. Türkiye örnekleminin %24’ünde koroner kalp hastalığı (KKH) olduğu ölçüldü. Kalp yetersizliği (%5,4) en sık saptanan 2. KVH alt tipiyken, kardiyak aritmi ve ileti anormalliklerini (%4,7) kalp yetersizliği takip etmektedir. Kardiyovasküler yararı kanıtlanmış ilaçlardan sodyum glukoz transport-2 inhibitörleri ve glukagon benzeri peptid-1 reseptör agonistlerinin reçete edilme oranları sırasıyla %17,5 ve %0,1 olarak saptanmıştır. Sonuç: Türkiye’deki T2DM hastalarında KVH, küresel CAPTURE popülasyonunda bulunan prevalansa benzer şekilde hastaların yaklaşık %30’unda saptanmıştır. KKKH en sık saptanan hastalık olurken, KVH vakalarının %75'ini oluşturmuştur. Kardiyovasküler yararı olan glukoz düşürücü ilaçların kullanımı, muhtemelen bu ilaçların Türkiye’de geri ödenmemesi nedeniyle küresel havuzdaki nüfusa kıyasla düşüktü.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Ilkova H, Damcı T, Karşıdağ K, Çömlekçi A, Ayvaz G. The International Diabetes Management Practices Study (IDMPS) - Turkey's 5th wave results. Turk J Endocrinol Metab. 2016;20:88-96. [Crossref]
  • 2. Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary prevention of cardiovascular disease in diabetes mellitus. J Am Coll Cardiol. 2017;70:883-893. [Crossref] [Pubmed] [PMC]
  • 3. T.C. Sağlık Bakanlığı. Türkiye Beslenme ve Sağlık Araştırması. Saha Uygulaması El Kitabı. Ankara: Tiraj Basım ve Yayın Sanayi Ticaret Ltd. Şti.; 2019. [Link]
  • 4. Sonmez A, Haymana C, Bayram F, Salman S, Dizdar OS, Gurkan E, Kargili Carlıoglu A, Barcin C, Sabuncu T, Satman I; TEMD Study Group. Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study). Diabetes Res Clin Pract. 2018;146:138-147. [Pubmed]
  • 5. Kozan Ö, Zoghi M, Ergene O, Arıcı M, Derici Ü, Bakaç G, Güllü S, Sain Güven G; PRE-CONTROL Study Investigators. Prevention and Control Program for Cardiovascular Diseases in Turkish Population: PRE-CONTROL Study Group. Glob Heart. 2013;8:115-119. [Crossref] [Pubmed]
  • 6. Taşçı C, Ozçelik N. An overview on coronary heart disease (a comparative evaluation of turkey and europe) and cost-effectiveness of diagnostic strategies. Mol Imaging Radionucl Ther. 2011;20:75-93. [Crossref] [Pubmed] [PMC]
  • 7. Einarson TR, Acs A, Ludwig C, Panton UH. Economic burden of cardiovascular disease in Type 2 diabetes: a systematic review. Value Health. 2018;21:881- 890. [Crossref] [Pubmed]
  • 8. The Society of Endocrinology and Metabolism of Turkey (SEMT). Clinical Practice Guideline for Diagnosis, Treatment, and Follow-Up of Diabetes Mellitus and Its Complications. 12th ed. Ankara: Bilimsel Araştırmalar Basın Yayın ve Tanıtım Ltd. Şti.; 2019.
  • 9. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D'Alessio DA, Davies MJ. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487-493. Erratum in: Diabetes Care. 2020;43:1670. [Crossref] [Pubmed] [PMC]
  • 10. US Food and Drug Administration. Guidance for industry: Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Vol 2019. 2008. Accessed: 23 Sep 21. [Link]
  • 11.Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323. Erratum in: Eur Heart J. 2020;41:4317. [Pubmed]
  • 12. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Mu-oz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140: e563-e595. Erratum in: Circulation. 2019;140:e647- e648. Erratum in: Circulation. 2020;141:e59. Erratum in: Circulation. 2020;141:e773. [Pubmed] [PMC]
  • 13.American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S111-S124. [Crossref] [Pubmed]
  • 14. International Diabetes Federation [Internet]. © 2022 International Diabetes Federation [Cited: ]. IDF Diabetes Atlas, ninth edition. 2019. Accessed: 23 Sep 21 Available from: [Link]
  • 15.Malhan S, Öksüz E, Babineaux SM, Ertekin A, Palmer JP. Assessment of the direct medical costs of Type 2 diabetes mellitus and its complications in Turkey. Turk J Endocrinol Metab. 2014;2:39-43. [Crossref]
  • 16.Küçükler F, Küçükardali Y, Başpinar O, Çalan M, Çitirik Ç, Çolak R, Sari R, Araz M, Tetiker T, Bayram F. Multiple cardiovascular risk factors management according to guidelines in patients initiating secondline glucose-lowering treatment in Turkey: Results from the global DISCOVER study. Turk J Endocrinol Metab. 2018;22:S15-S16. [Crossref]
  • 17. Onat A, Hergenç G, Uyarel H, Can G, Ozhan H. Prevalence, incidence, predictors and outcome of type 2 diabetes in Turkey. Anadolu Kardiyol Derg. 2006;6:314-321. [Pubmed]
  • 18.Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, Dieuzeide G, Eriksen KT, Hong T, Kaltoft MS, Lengyel C, Rhee NA, Russo GT, Shirabe S, Urbancova K, Vencio S, Investigators CS. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovascular Diabetology. 2021;20:154. [Crossref] [Pubmed] [PMC]
  • 19.World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194. [Crossref] [Pubmed]
  • 20. International Society for Pharmacoepidemiology [Internet]. Copyright 2022 International Society for Pharmacoepidemiology [Cited: ]. Guidelines for Good Pharmacoepidemiology Practices (GPP). 2021. 2015. Accessed: 10 Nov 21. [Link]
  • 21. Haymana C, Sonmez A, Demirci I, Fidan Yaylalı G, Nuhoglu I, Sancak S, Yilmaz M, Altuntas Y, Dinccag N, Sabuncu T, Bayram F, Satman I; TEMD Study Group. Patterns and preferences of antidiabetic drug use in Turkish patients with type 2 diabetes - A nationwide cross-sectional study (TEMD treatment study). Diabetes Res Clin Pract. 2021;171:108556. [Crossref] [Pubmed]
  • 22. Ndumele CD, Baer HJ, Shaykevich S, Lipsitz SR, Hicks LS. Cardiovascular disease and risk in primary care settings in the United States. Am J Cardiol. 2012;109:521-526. [Crossref] [Pubmed] [PMC]
  • 23. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:1228-1239. [Crossref] [Pubmed]
  • 24.American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43:S98-S110. Erratum in: Diabetes Care. 2020;43:1979. [Crossref] [Pubmed]
APA bayram f, BAYRAKTAROĞLU T, SARGIN M, Sahin i, GÜLDİKEN S, Dalbeler A, Sonmez A (2022). A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. , 1 - 12.
Chicago bayram fahri,BAYRAKTAROĞLU TANER,SARGIN MEHMET,Sahin ibrahim,GÜLDİKEN SİBEL,Dalbeler Aysegul,Sonmez Alper A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. (2022): 1 - 12.
MLA bayram fahri,BAYRAKTAROĞLU TANER,SARGIN MEHMET,Sahin ibrahim,GÜLDİKEN SİBEL,Dalbeler Aysegul,Sonmez Alper A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. , 2022, ss.1 - 12.
AMA bayram f,BAYRAKTAROĞLU T,SARGIN M,Sahin i,GÜLDİKEN S,Dalbeler A,Sonmez A A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. . 2022; 1 - 12.
Vancouver bayram f,BAYRAKTAROĞLU T,SARGIN M,Sahin i,GÜLDİKEN S,Dalbeler A,Sonmez A A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. . 2022; 1 - 12.
IEEE bayram f,BAYRAKTAROĞLU T,SARGIN M,Sahin i,GÜLDİKEN S,Dalbeler A,Sonmez A "A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study." , ss.1 - 12, 2022.
ISNAD bayram, fahri vd. "A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study". (2022), 1-12.
APA bayram f, BAYRAKTAROĞLU T, SARGIN M, Sahin i, GÜLDİKEN S, Dalbeler A, Sonmez A (2022). A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. Turkish Journal of Endocrinology and Metabolism, 26(1), 1 - 12.
Chicago bayram fahri,BAYRAKTAROĞLU TANER,SARGIN MEHMET,Sahin ibrahim,GÜLDİKEN SİBEL,Dalbeler Aysegul,Sonmez Alper A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. Turkish Journal of Endocrinology and Metabolism 26, no.1 (2022): 1 - 12.
MLA bayram fahri,BAYRAKTAROĞLU TANER,SARGIN MEHMET,Sahin ibrahim,GÜLDİKEN SİBEL,Dalbeler Aysegul,Sonmez Alper A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. Turkish Journal of Endocrinology and Metabolism, vol.26, no.1, 2022, ss.1 - 12.
AMA bayram f,BAYRAKTAROĞLU T,SARGIN M,Sahin i,GÜLDİKEN S,Dalbeler A,Sonmez A A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. Turkish Journal of Endocrinology and Metabolism. 2022; 26(1): 1 - 12.
Vancouver bayram f,BAYRAKTAROĞLU T,SARGIN M,Sahin i,GÜLDİKEN S,Dalbeler A,Sonmez A A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study. Turkish Journal of Endocrinology and Metabolism. 2022; 26(1): 1 - 12.
IEEE bayram f,BAYRAKTAROĞLU T,SARGIN M,Sahin i,GÜLDİKEN S,Dalbeler A,Sonmez A "A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study." Turkish Journal of Endocrinology and Metabolism, 26, ss.1 - 12, 2022.
ISNAD bayram, fahri vd. "A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study". Turkish Journal of Endocrinology and Metabolism 26/1 (2022), 1-12.